Capricor Therapeutics Shares Updates on DMD Program
Capricor Therapeutics (NASDAQ: CAPR) is gearing up to provide important updates about its Duchenne muscular dystrophy (DMD) program during an investor webcast. Set for 8:30 a.m. ET, this event will cover key regulatory advancements following recent discussions with the U.S. Food and Drug Administration.
Webcast Details
Participants in the conference call can engage directly by calling the numbers provided. For those in the United States, the toll-free number is 1-800-717-1738, while international attendees can reach the call at 1-646-307-1865. By using the conference ID: 62574, they will gain access to the discussion. Alternatively, attendees may join the webcast to view presentation slides that accompany the event.
Accessing the Webcast Replay
The webinar will be available for replay shortly after the live session ends, allowing stakeholders and interested parties to revisit the critical information shared.
About Capricor Therapeutics
Capricor Therapeutics is dedicated to developing innovative cell and exosome-based therapies that aim to transform treatment strategies for rare diseases. Their lead candidate, deramiocel (CAP-1002), represents a pioneering allogeneic cardiac-derived cell therapy. Clinical trials have demonstrated its promise in modulating immune responses and fostering healing, especially in cases of DMD and certain heart ailments.
Advancements with Deramiocel
Currently, deramiocel is advancing through Phase 3 clinical trials aimed at treating DMD, showing encouraging results from earlier studies that back its effectiveness. Capricor’s unique exosome technology is also being developed to improve drug delivery and address various health conditions through its proprietary StealthX™ platform.
Capricor's Commitment to Innovation
Capricor’s mission is driven by a strong commitment to enhance the lives of individuals affected by rare disorders. By pouring resources into research and clinical trials, the company strives to deliver groundbreaking solutions for patients in need. Their recent collaboration with Nippon Shinyaku Co., Ltd. to commercialize deramiocel marks a crucial step toward achieving these objectives, pending necessary regulatory approvals.
Strategic Vision of the Company
The company believes that with strategic partnerships and ongoing research, it can leverage its technologies to develop effective therapies. Capricor's forward-thinking strategies position it at the forefront of one of healthcare's most pressing challenges: redefining treatments for rare diseases.
Frequently Asked Questions
What will Capricor Therapeutics discuss in the upcoming webcast?
The webcast will focus on updates about the Duchenne muscular dystrophy program and will cover recent interactions with the FDA on regulatory advancements.
How can stakeholders take part in the Capricor conference call?
Stakeholders can join the call using the provided telephone numbers and must use the conference ID: 62574 to connect.
What is deramiocel (CAP-1002)?
Deramiocel is an allogeneic cardiac-derived cell therapy that's currently being tested in Phase 3 trials for Duchenne muscular dystrophy.
How are exosomes utilized in Capricor's therapy development?
Capricor employs its proprietary StealthX™ platform to enhance the targeted delivery of therapeutics through advanced exosome technology.
Who should be contacted for more information about Capricor’s programs?
For more information, interested individuals can reach out to Raquel Cona or AJ Bergmann, whose contact details are available in the company's media contact information.
